This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Risperidone Augmentation in Patients With Schizophrenia

This study has been completed.
Stanley Medical Research Institute
Information provided by (Responsible Party):
Oliver Freudenreich, Massachusetts General Hospital Identifier:
First received: February 8, 2006
Last updated: October 29, 2013
Last verified: October 2013
We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.

Condition Intervention Phase
Schizophrenia Drug: Risperidone Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine

Resource links provided by NLM:

Further study details as provided by Oliver Freudenreich, Massachusetts General Hospital:

Primary Outcome Measures:
  • Our primary outcome measure will be change in total score on the Positive and Negative Symptom Scale (PANSS).

Enrollment: 24
Study Start Date: February 2003
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: risperdone Drug: Risperidone
Placebo Comparator: placebo Drug: placebo

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Clinical DSM-IV diagnosis of schizophrenia (any subtype) based on chart review and patient interview by research psychiatrist
  2. Ages 18-65
  3. Stable residual psychiatric symptoms defined as PANSS score greater than 60
  4. On clozapine monotherapy with plasma level of at least 200 ng/mL (unless the patient refuses a dose adjustment or does not tolerate a higher dose)
  5. On clozapine for at least 6 months and at a stable dose for at least 8 weeks
  6. Competent to provide informed consent. If the subject has a guardian, assent must be given by the subject and consent must be given by the guardian.

Exclusion Criteria:

  1. Chart diagnosis of dementia or another neurodegenerative disorder, mental retardation, or a pervasive developmental disorder
  2. Suicidal ideation
  3. Substance use disorder (excluding nicotine use) in the past 3 months
  4. Any unstable medical illness
  5. Pregnancy or breast-feeding
  6. Investigational agent in past 30 days
  7. History of adverse reaction to risperidone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00289861

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Stanley Medical Research Institute
Principal Investigator: Oliver Freudenreich, M.D. MGH
Principal Investigator: Donald C Goff, M.D. MGH
  More Information

Responsible Party: Oliver Freudenreich, Medical Director, MGH Schizophrenia Program, Massachusetts General Hospital Identifier: NCT00289861     History of Changes
Other Study ID Numbers: 2002-P-000584
Study First Received: February 8, 2006
Last Updated: October 29, 2013

Keywords provided by Oliver Freudenreich, Massachusetts General Hospital:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
GABA Antagonists
GABA Agents processed this record on August 21, 2017